Moderna's RSV vaccine shown to provide strong protection against serious cases in adults 50 and older

A study of U.S. veterans shows that Moderna's mResvia RSV vaccine provides strong protection against severe illness and hospitalization in adults aged 50 and older. While effectiveness remains high, the study noted that protection levels decrease as patients age.
Why it matters
Validating vaccine efficacy in older populations is critical for public health strategies aimed at reducing the burden of respiratory infections on healthcare systems.
by Stephanie Soucheray, University of Minnesota
edited by Lisa Lock , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources Credit: cottonbro studio from Pexels A single dose of Moderna's mResvia RSV vaccine was 60.3% protective against documented respiratory syncytial virus (RSV) infections, 60.2% against RSV-associated emergency department or urgent care encounters and 81.8% against RSV-associated hospitalizations in a population of older U.S. veterans, according to a recent study in JAMA Network Open .
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in